Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Hematologic Neoplasms 2 HER2-positive Breast Cancer 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoproliferative Disorders 1 Lung Neoplasms 1 Gallbladder Neoplasms 1 Colorectal Neoplasms 1

Interventions

Oxaliplatin 11 Docetaxel 8 Fluorouracil 6 Capecitabine 6 Trastuzumab 5 Leucovorin 5 Drug Therapy 5 apatinib 4 S 1 (combination) 4 Tegafur 3 Paclitaxel 3 Nivolumab 3 Irinotecan 3 Cisplatin 3 sintilimab 2 disitamab vedotin 2 Surgical Procedures, Operative 2 Standard of Care 2 Ramucirumab 2 Hyperthermic Intraperitoneal Chemotherapy 2 Epirubicin 2 vinflunine 1 toripalimab 1 titanium silicide 1 tislelizumab 1 taxane 1 polysaccharide-K 1 pertuzumab 1 margetuximab 1 gimeracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Stomach Neoplasms × pertuzumab × Clear all

NCT02581462 2020-08-11

PETRARCA

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2/3 Completed

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡